All In Biotech

Drug Trial Radar · NCT06225544

Lumasiran in Hyperoxalaemic Patients on Haemodialysis

Last checked: Nov 20, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 14, 2024

Primary completion

Jan 30, 2025

Study completion Mar 1, 2025

Sponsor

Lead sponsor
Charite University, Berlin, GermanyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Alnylam Pharmaceuticals
First posted
Jan 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how well a drug that reduced the amount of oxalate in the body works in patients that have kidney disease and need dialysis treatment. People with kidney disease often have higher levels of oxalate in the blood. People with kidney disease are also at higher risk of having heart attacks, heart disease and strokes (these are called cardiovascular diseases). It is thought that high oxalate levels may increase the risk of these diseases. This study will investigate if this medicine can lower the amount of oxalate in the blood of dialysis patients and see if there is any change in the health of their heart. This medicine is already used for people who have high oxalate levels because of a genetic cause and has been used safely for patients on dialysis. The study will put the participants randomly into either the group getting the study medicine or the group getting a placebo (this will be a solution of saline water). Neither participants not the doctors will know whether the drug or placebo is given until after the end of the study. At the start of the study all the participants will have an echocardiogram (an ultrasound of the heart) and again 6 months later at the end of the study. We will also take blood tests once a month when the participants come for dialysis.

Conditions

  • Haemodialysis
  • Chronic Kidney Disease Requiring Chronic Dialysis
  • Cardiovascular Disease
  • Cardiovascular Risk Factor
  • Hyperoxalemia

Interventions

  • LumasiranDrug

    Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.

  • 0.9% Sodium Chloride (placebo)Drug

    Placebo, subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pre-dialysis Plasma Oxalate concentrationTime frame: It will be measured at baseline and month 1-6 (weeks 4, 8, 12, 16, 20 and 24).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Charite Universtiätsmedizin

    Berlin, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.